The JCVI set out its final recommendations on phase two of the vaccine programme on Feb 26, concluding that those aged 40-49 will be first in line to receive a vaccine invite.
Those aged 30-39 and 18-29 will then be next to be invited, with the Government aiming to have all adults vaccinated by the end of July, raising hopes for the possibility of outdoor events and holidays in August.
Professor Wei Shen Lim, Covid-19 chair for JCVI, said: “Vaccinations stop people from dying and the current strategy is to prioritise those who are more likely to have severe outcomes and die from Covid-19.
“The evidence is clear that the risk of hospitalisation and death increases with age.
“The vaccination programme is a huge success and continuing the age-based rollout will provide the greatest benefit in the shortest time, including to those in occupations at a higher risk of exposure.”
Why is there a delay between the first and second jabs?
Regulators have said the key to success will be to administer two full doses between four to 12 weeks apart, in order to give as many people the initial dose of the vaccine as possible, which offers some protection from the virus.
A study found a single dose of the Oxford vaccine was 76 per cent effective in fending off infection between 22 days and 90 days post-injection, rising to 82.4 per cent after a second dose at that stage. Researchers involved in the trial said the findings support the decision made by the UK to extend the interval between initial doses and booster doses of the shot to 12 weeks.
A study found that a single dose of the Pfizer/BioNTech vaccine provided a “very high” level of protection from Covid-19 after just 21 days, without the need for a second “top-up” vaccination.
The UEA study, which has not yet been peer reviewed, looked at data from Israel where the vaccine has been rolled out. Scientists found the vaccine becomes 90 per cent effective after 21 days – supporting UK plans to delay the timing of a second jab.
While it is not yet known how long immunity lasts beyond 21 days without a second dose, researchers believe it is “unlikely” to majorly decline during the following nine weeks.
Read more: From transmission to efficacy, the Oxford, Pfizer and other Covid vaccines compared
How will I be invited to get the vaccine?
The NHS will contact you when you are eligible for the vaccine and you will be invited to make an appointment.
If you are registered to a GP, you will be contacted by your surgery either over the phone, by text, email or post, in order to book in to receive a vaccine at your local vaccination centre.
You can still register at a GP surgery if you are not already registered to one, and it is advised that you make sure that your contact details are up to date to ensure that there are no delays.
However, if you are over 70 and have not yet received the vaccine, the government urges you to contact your GP.
Three modes of delivery
Health Secretary Matt Hancock said there would be “three modes of delivery”, with hospitals and mass vaccination centres along with pharmacists and GPs offering the jab.
In total, 250 active hospital sites, 89 vaccination centres, and around 1,200 local vaccination sites – including primary care networks, community pharmacy sites and mobile teams – have been set up to ensure every at-risk person has easy access to a vaccination centre, regardless of where they live.
Sites across the country have been transformed into vaccine hubs and started administering vaccines from Jan 25.
Some of these venues include ExCel in London, Villa Park in Birmingham, Etihad Tennis Centre in Manchester and Epsom Downs Racecourse in Surrey.
Mr Johnson has promised that vaccines would be available to people within 10 miles of their home. For a small number of highly rural areas, the vaccine will be brought to them via mobile teams.
Alongside the three modes of delivery, the Vaccines Minister, Nadhim Zahawi has said that there is potential that the vaccine could be administered in the form of a pill.
Receiving a vaccine dose in pill form could help alleviate supply issues that have hindered the rollout in some areas of the world including Europe.